跳至主要内容
临床试验/DRKS00023744
DRKS00023744已完成未知

Clinical Study to Assess the Impact of a Bacterial- and Yeast-based Nutritional Supplement (AlcoDeTox) on Ethyl Alcohol Absorption in the Intestine Tract

Peradil AB0 个研究点目标入组 24 人开始时间: 2020年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
24

研究概览

简要总结

There was a significant reduction of blood alcohol levels by 70.3 % (p < 0.005) with AB001, when compared to placebo. There was a less pronounced but also significant reduction of alcohol in the breath test 30.7 % (p < 0.005), when compared to placebo. No difference in the cognitive function test between AB001 and placebo could be observed 60 min after alcohol ingestion (22.4±7.7 s vs. 22.7±5.6, n.s.). The supplement uptake was well tolerated. There were no adverse events or serious adverse events reported in this study

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • 1. Age > 18 years and = 75 years
  • 2. Caucasian
  • 3. Not suffering from any major disease
  • 4. Willing to perform the two drinking experiments
  • 5. No alcohol consumption within 7 days prior to study participation (negative EtG urine test
  • 6. Negative Drug Screening test
  • 7. Negative pregnancy test

排除标准

  • 1. Acute or chronic disease
  • 2. Present or History of alcohol addiction
  • 3. Known allergy against probiotic nutritional supplements
  • 4. Participation in a clinical trial within 3 months before trial entry.
  • 5. Progressive fatal diseases
  • 6. Participants taking medication (including non-prescription drugs)
  • 7. Participants taking other dietary supplements
  • 8. Past or current drug or alcohol abuse
  • 9. Pregnancy or breast feeding
  • 10. Lack of compliance or other similar reason, that, the investigator believes, precludes satisfactory participation in the study

研究者

发起方
Peradil AB

相似试验

Clinical Study to Assess the Impact of a Bacterial-... | 临床试验